Temasek Life Sciences Accelerator

TLA sources its deal flow primarily through Singapore's Agency for Science, Technology and Research (A*STAR) and the broader public research university system. The firm evaluates inventions and research programs with commercial potential, then works with the originating scientists to form companies around the intellectual property. This captive sourcing model, built on exclusive or preferential access to A*STAR's research pipeline, gives TLA a proprietary deal channel that external VCs cannot replicate.

TLA's portfolio companies often raise follow-on funding from external VCs, and the firm's incubation model is designed to prepare startups for syndicated Series A rounds. While TLA itself remains a Temasek-backed entity and does not operate as an open fund, its startups benefit from introductions to global life science investors through the Temasek network. Co-investment at the institutional level is not part of TLA's mandate; its role is as company builder and seed investor.